Core Insights - The core viewpoint of the article highlights the financial performance of Yabao Pharmaceutical in the first half of 2025, indicating a significant decline in both revenue and net profit compared to the previous year [1] Financial Performance - Yabao Pharmaceutical reported a revenue of approximately 1.139 billion yuan, representing a year-on-year decrease of 21.08% [1] - The net profit attributable to shareholders was about 174 million yuan, showing a year-on-year decline of 2.99% [1] Reasons for Decline - The company attributed the revenue decline to decreased sales from several products, including the anti-inflammatory pain relief patch, Betahistine injection, and children's throat relief oral solution, as well as a drop in revenue from pharmaceutical wholesale business [1]
亚宝药业上半年净利1.74亿元,同比下降2.99%